Current perspectives between metabolic syndrome and cancer

被引:85
作者
Micucci, Carla [1 ]
Valli, Debora [1 ]
Matacchione, Giulia [1 ]
Catalano, Alfonso [1 ]
机构
[1] Polytech Univ Marche, Sch Med, Dept Clin & Mol Sci, Ancona, Italy
关键词
metabolic syndrome; cancer risk; visceral adiposity; hyperglycemia; inflammation; GROWTH-FACTOR-I; ENDOTHELIAL PROGENITOR CELLS; MESENCHYMAL STEM-CELLS; LONG-TERM SURVIVORS; BODY-MASS INDEX; BREAST-CANCER; PROSTATE-CANCER; ENDOMETRIAL CANCER; SUCCINATE-DEHYDROGENASE; INSULIN-RESISTANCE;
D O I
10.18632/oncotarget.8341
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metabolic syndrome is a cluster of risk factors that lead to cardiovascular morbidity and mortality. Recent studies linked metabolic syndrome and several types of cancer. Although metabolic syndrome may not necessarily cause cancer, it is linked to poorer cancer outcomes including increased risk of recurrence and overall mortality. This review tends to discuss the major biological and physiological alterations involved in the increase of incidence and mortality of cancer patients affected by metabolic syndrome. We focus on metabolic syndrome-associated visceral adiposity, hyperinsulinemia, hyperglycemia, insulin-like growth factor (IGF-I) pathway as well as estrogen signaling and inflammation. Several of these factors are also involved in carcinogenesis and cancer progression. A better understanding of the link between metabolic syndrome and cancer may provide new insight about oncogenesis. Moreover, prevention of metabolic syndrome-related alterations may be an important aspect in the management of cancer patients during simultaneous palliative care.
引用
收藏
页码:38959 / 38972
页数:14
相关论文
共 116 条
[11]   Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis [J].
Bråkenhielm, E ;
Veitonmäki, N ;
Cao, RH ;
Kihara, S ;
Matsuzawa, YJ ;
Zhivotovsky, B ;
Funahashi, T ;
Cao, YH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (08) :2476-2481
[12]   The Link between the Metabolic Syndrome and Cancer [J].
Braun, Sandra ;
Bitton-Worms, Keren ;
LeRoith, Derek .
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2011, 7 (07) :1003-1015
[13]   INSULIN-LIKE GROWTH-FACTOR-BINDING PROTEIN-3 IS DECREASED IN EARLY-STAGE OPERABLE PREMENOPAUSAL BREAST-CANCER [J].
BRUNING, PF ;
VANDOORN, J ;
BONFRER, JMG ;
VANNOORD, PAH ;
KORSE, CM ;
LINDERS, TC ;
HART, AAM .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (03) :266-270
[14]   Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth [J].
Buzzai, Monica ;
Jones, Russell G. ;
Amaravadi, Ravi K. ;
Lum, Julian J. ;
DeBerardinis, Ralph J. ;
Zhao, Fangping ;
Viollet, Benoit ;
Thompson, Craig B. .
CANCER RESEARCH, 2007, 67 (14) :6745-6752
[15]   Regulation of cancer cell metabolism [J].
Cairns, Rob A. ;
Harris, Isaac S. ;
Mak, Tak W. .
NATURE REVIEWS CANCER, 2011, 11 (02) :85-95
[16]   Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults [J].
Calle, EE ;
Rodriguez, C ;
Walker-Thurmond, K ;
Thun, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1625-1638
[17]   Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[18]   The metabolic syndrome: prevalence in worldwide populations [J].
Cameron, AJ ;
Shaw, JE ;
Zimmet, PZ .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2004, 33 (02) :351-+
[19]   Plasma insulin-like growth factor I and prostate cancer risk: A prospective study [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, E ;
Gann, PH ;
Ma, J ;
Wilkinson, P ;
Hennekens, CH ;
Pollak, M .
SCIENCE, 1998, 279 (5350) :563-566
[20]   IGF-1R as an anti-cancer target-trials and tribulations [J].
Chen, Helen X. ;
Sharon, Elad .
CHINESE JOURNAL OF CANCER, 2013, 32 (05) :242-252